Assessing recent recurrence after hepatectomy for hepatitis B-related hepatocellular carcinoma by a predictive model based on sarcopenia

Table 2 Baseline characteristics of and biochemical data of hepatocellular carcinoma patients in the training cohort

Characteristic	Total (n = 189)	Recurrence group (n = 104)	Non-recurrence group (n = 85)	P value
Age (yr)	52.86 ± 11.65	51.92 ± 11.42	54 ± 11.88	0.751
Gender, n (%)				0.579
Male	163 (86.2)	91 (87.5)	72 (84.7)
Female	26 (13.8)	13 (12.5)	13 (15.3)
Sarcopenia, n (%)	54 (28.6)	36 (66.7)	18 (33.3)	0.042
Liver cirrhosis, n (%)	105 (55.6)	55 (52.4)	50 (47.6)	0.414
MVI, n (%)	89 (47.1)	56 (62.9)	33 (37.1)	0.04
Tumor differentiation, n (%)				0.008
Poor	33 (17.5)	22 (66.7)	11 (33.3)
Moderate	81 (42.9)	51 (63.0)	30 (37.0)
Well	75 (39.6)	31 (41.3)	44 (58.7)
Liver capsular invasion	112 (59.3)	67 (59.8)	45 (40.2)	0.11
Maximum diameter of tumor, n (%)				0.003
≤ 3 cm	40 (21.2)	16 (40.0)	25 (60.0)
3-5 cm	43 (22.8)	18 (41.9)	25 (58.1)
> 5 cm	106 (56.1)	70 (66.0)	38 (34.0)
HBV-DNA, n (%)				0.002
< 2000 IU/mL	127 (67.2)	60 (47.2)	67 (52.8)
≥ 2000 IU/mL	62 (32.8)	44 (71.0)	20 (29.0)
AFP ≥ 40 ng/mL	106 (56.1)	70 (66.0)	36 (34.0)	0.001
ALT, U/L	36 (26-51.75)	36 (28-52.75)	36 (22.25-51)	0.481
Total bilirubin (mmol/L)	14.80 (11.15-22.02)	15.90 (12.15-23.15)	14.3 (10.55-19.70)	0.051
Albumin, g/L	40.52 (35.43-43.98)	39.05 (34.65-43.5)	41 (36.62-44.48)	0.096
INR	1.01 (0.94-1.08)	1.0 (0.95-1.07)	1.01 (0.93-1.09)	0.846
Leukocyte, 109/L	5.38 (4.37-6.49)	5.38 (4.24-6.79)	5.39 (4.5-6.36)	0.921
PLT, 109/L	162 (109-220)	147 (100-200)	176 (116-234)	0.056

MVI: Microvascular invasion; HBV-DNA: Hepatitis B virus deoxyribonucleic acid; AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; INR: International normalized ratio; PLT: Platelet count.